O	0	1	A
O	2	15	Nonrandomized
O	15	16	,
O	17	22	Phase
O	23	25	II
O	26	31	Study
O	32	34	of
B-intervention	35	45	Sequential
I-intervention	46	56	Irinotecan
I-intervention	57	60	and
I-intervention	61	73	Flavopiridol
O	74	76	in
O	77	85	Patients
O	86	90	With
O	91	99	Advanced
O	100	114	Hepatocellular
O	115	124	Carcinoma
O	124	125	.

O	126	138	Flavopiridol
O	138	139	,
O	140	141	a
O	142	145	Cdk
O	146	155	inhibitor
O	155	156	,
O	157	168	potentiates
O	169	179	irinotecan
O	179	180	-
O	180	187	induced
O	188	197	apoptosis
O	197	198	.

O	199	201	In
O	202	203	a
O	204	209	phase
O	210	211	I
O	212	217	trial
O	218	220	of
O	221	231	sequential
O	232	242	irinotecan
O	243	246	and
O	247	259	flavopiridol
O	259	260	,
O	261	262	2
O	263	271	patients
O	272	276	with
O	277	285	advanced
O	286	300	hepatocellular
O	301	310	carcinoma
O	311	312	(
O	312	315	HCC
O	315	316	)
O	317	320	had
O	321	327	stable
O	328	335	disease
O	336	337	(
O	337	339	SD
O	339	340	)
O	341	344	for
O	345	346	≥
O	346	348	14
O	349	355	months
O	355	356	.

O	357	359	We
O	360	364	thus
O	365	372	studied
O	373	376	the
O	377	387	sequential
O	388	399	combination
O	400	402	of
O	403	413	irinotecan
O	414	417	and
O	418	430	flavopiridol
O	431	433	in
O	434	442	patients
O	443	447	with
O	448	451	HCC
O	451	452	.

B-eligibility	453	461	Patients
I-eligibility	462	466	with
I-eligibility	467	475	advanced
I-eligibility	476	479	HCC
I-eligibility	480	482	na
I-eligibility	482	483	ï
I-eligibility	483	485	ve
I-eligibility	486	488	to
I-eligibility	489	497	systemic
I-eligibility	498	505	therapy
O	505	506	,
O	507	512	Child
O	512	513	-
O	513	517	Pugh
O	518	519	≤
O	519	521	B8
O	521	522	,
O	523	526	and
O	527	536	Karnofsky
O	537	548	performance
O	549	554	score
O	555	556	(
O	556	559	KPS
O	559	560	)
O	561	562	≥
O	562	564	70
O	564	565	%
O	566	574	received
O	575	578	100
O	579	581	mg
O	581	582	/
O	582	583	m
O	583	584	(
O	584	585	2
O	585	586	)
O	587	597	irinotecan
O	598	606	followed
O	607	608	7
O	609	614	hours
O	615	620	later
O	621	623	by
O	624	636	flavopiridol
O	637	639	60
O	640	642	mg
O	642	643	/
O	643	644	m
O	644	645	(
O	645	646	2
O	646	647	)
O	648	654	weekly
O	655	658	for
O	659	660	4
O	661	663	of
O	664	665	6
O	666	671	weeks
O	671	672	.

O	673	676	The
O	677	684	primary
O	685	688	end
O	689	694	point
O	695	698	was
O	699	701	an
B-outcome-Measure	702	713	improvement
I-outcome-Measure	714	716	in
I-outcome-Measure	717	728	progression
I-outcome-Measure	728	729	-
I-outcome-Measure	729	733	free
I-outcome-Measure	734	742	survival
I-outcome-Measure	743	745	at
I-outcome-Measure	746	747	4
I-outcome-Measure	748	754	months
I-outcome-Measure	755	756	(
I-outcome-Measure	756	759	PFS
I-outcome-Measure	759	760	-
I-outcome-Measure	760	761	4
I-outcome-Measure	761	762	)
O	763	767	from
O	768	770	33
O	770	771	%
O	772	774	to
O	775	777	54
O	777	778	%
O	778	779	,
O	780	785	using
O	786	787	a
O	788	793	Simon
O	793	794	'
O	794	795	s
O	796	799	two
O	799	800	-
O	800	805	stage
O	806	812	design
O	812	813	.

O	814	820	Tumors
O	821	825	were
O	826	833	stained
O	834	837	for
O	838	841	p53
O	841	842	.

O	843	847	Only
B-total-participants	848	850	16
O	851	859	patients
O	860	862	in
O	863	866	the
O	867	872	first
O	873	878	stage
O	879	883	were
O	884	892	enrolled
O	892	893	:
O	894	900	median
O	901	904	age
O	904	905	,
B-age	906	908	64
I-age	909	914	years
O	914	915	;
O	916	922	median
O	923	926	KPS
O	926	927	,
O	928	930	80
O	930	931	%
O	931	932	;
O	933	938	Child
O	938	939	-
O	939	943	Pugh
O	944	945	A
O	945	946	,
O	947	949	87
O	949	950	.
O	950	951	5
O	951	952	%
O	952	953	;
O	954	957	and
O	958	963	stage
O	964	967	III
O	967	968	/
O	968	970	IV
O	970	971	,
O	972	974	25
O	974	975	%
O	975	976	/
O	976	978	75
O	978	979	%
O	979	980	.

O	981	984	The
O	985	992	primary
O	993	996	end
O	997	1002	point
O	1003	1006	was
O	1007	1010	not
O	1011	1014	met
O	1014	1015	;
B-outcome	1016	1019	PFS
I-outcome	1019	1020	-
I-outcome	1020	1021	4
O	1022	1025	was
O	1026	1028	20
O	1028	1029	%
O	1029	1030	,
O	1031	1038	leading
O	1039	1041	to
O	1042	1047	early
O	1048	1059	termination
O	1060	1062	of
O	1063	1066	the
O	1067	1072	study
O	1072	1073	.

O	1074	1077	Ten
O	1078	1086	patients
O	1087	1091	were
O	1092	1101	evaluable
O	1102	1105	for
O	1106	1114	response
O	1114	1115	:
B-iv-bin-abs	1116	1117	1
O	1118	1121	had
B-outcome	1122	1124	SD
I-outcome	1125	1126	>
I-outcome	1126	1127	1
O	1128	1132	year
O	1133	1136	and
B-iv-bin-abs	1137	1138	9
O	1139	1142	had
B-outcome	1143	1150	disease
I-outcome	1151	1162	progression
O	1162	1163	.

B-outcome	1164	1169	Grade
I-outcome	1170	1171	3
I-outcome	1172	1179	fatigue
O	1179	1180	,
B-outcome	1181	1192	dehydration
O	1192	1193	,
B-outcome	1194	1202	diarrhea
O	1202	1203	,
B-outcome	1204	1215	neutropenia
I-outcome	1216	1220	with
I-outcome	1221	1223	or
I-outcome	1224	1231	without
I-outcome	1232	1237	fever
O	1237	1238	,
B-outcome	1239	1250	lymphopenia
O	1250	1251	,
B-outcome	1252	1258	anemia
O	1258	1259	,
B-outcome	1260	1278	hyperbilirubinemia
O	1278	1279	,
O	1280	1283	and
B-outcome	1284	1297	transaminitis
O	1298	1306	occurred
O	1307	1309	in
O	1310	1311	≥
O	1311	1313	10
O	1313	1314	%
O	1315	1317	of
O	1318	1321	the
O	1322	1330	patients
O	1330	1331	.

O	1332	1334	Of
O	1335	1338	the
B-total-participants	1339	1340	9
O	1341	1349	patients
O	1350	1353	who
O	1354	1364	progressed
O	1364	1365	,
B-iv-bin-abs	1366	1367	5
O	1368	1371	had
B-outcome	1372	1378	mutant
I-outcome	1379	1382	p53
O	1383	1386	and
B-iv-bin-abs	1387	1388	4
O	1389	1392	had
B-outcome	1393	1397	wild
I-outcome	1397	1398	-
I-outcome	1398	1402	type
I-outcome	1403	1406	p53
O	1406	1407	.

O	1408	1411	The
O	1412	1419	patient
O	1420	1424	with
O	1425	1431	stable
O	1432	1439	disease
O	1440	1443	had
O	1444	1448	wild
O	1448	1449	-
O	1449	1453	type
O	1454	1457	p53
O	1457	1458	.

O	1459	1469	Sequential
O	1470	1480	irinotecan
O	1481	1484	and
O	1485	1497	flavopiridol
O	1498	1501	are
O	1502	1513	ineffective
O	1514	1517	and
O	1518	1524	poorly
O	1525	1534	tolerated
O	1535	1537	in
O	1538	1546	patients
O	1547	1551	with
O	1552	1560	advanced
O	1561	1564	HCC
O	1564	1565	.

O	1566	1573	Despite
O	1574	1577	our
O	1578	1585	limited
O	1586	1597	assessments
O	1597	1598	,
O	1599	1601	it
O	1602	1604	is
O	1605	1613	possible
O	1614	1618	that
O	1619	1622	the
O	1623	1631	presence
O	1632	1634	of
O	1635	1639	wild
O	1639	1640	-
O	1640	1644	type
O	1645	1648	p53
O	1649	1651	is
O	1652	1661	necessary
O	1662	1665	but
O	1666	1669	not
O	1670	1680	sufficient
O	1681	1683	to
O	1684	1691	predict
O	1692	1700	response
O	1701	1703	in
O	1704	1707	HCC
O	1707	1708	.
